Jefferies Lifts Numbers on Onyx Pharmaceuticals (ONXX)
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Price: $124.70 --0%
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Jefferies raised estiamtes and its price target on Onyx Pharmaceuticals (NASDAQ: ONXX) from $46 to $50 after including regorafenib mCRC royalties in their model.
The firm said the Q3 call was uneventful as management disclosed little on the carfilzomib NDA process, only guiding to a near term FDA acceptance decision.
FY11 EPS goes from ($2.84) to ($0.25), FY12 EPS from ($2.87) to ($2.42)
For more ratings news on Onyx Pharmaceuticals click here and for the rating history of Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $39.30 yesterday.
The firm said the Q3 call was uneventful as management disclosed little on the carfilzomib NDA process, only guiding to a near term FDA acceptance decision.
FY11 EPS goes from ($2.84) to ($0.25), FY12 EPS from ($2.87) to ($2.42)
For more ratings news on Onyx Pharmaceuticals click here and for the rating history of Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $39.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Upgrades Kingspan Group PLC (KSP:ID) to Buy
- Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight
- BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
